Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03216798
Other study ID # Client & Provider Preferences
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 15, 2017
Est. completion date July 15, 2025

Study information

Verified date April 2022
Source Thai Red Cross AIDS Research Centre
Contact Reshmie Ramautarsing, M.D., PhD.
Phone +662 253 0996
Email reshmie@trcarc.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will investigate preferences for HIV care among participants enrolled in the "Study to evaluate the feasibility of Community-based Test and Treat strategies among men who have sex with men and transgender women to increase the uptake of HIV testing and treatment services in Thailand" through a model involving linked strategies: The study takes place in four provinces at six sites affiliated with the Thai Red Cross AIDS Research Center (TRCARC): Bangkok (RSAT and SWING), Chiang Mai (CAREMAT), Chonburi (SWING and Sisters) and Songkhla (RSAT). These are all community-based drop-in centers, targeting MSM and TGW. Participants who are enrolled in the study at any of the TRCARC affiliated sites and who were tested HIV-positive will be invited to participate in the current questionnaire study.


Description:

This will be a cross-sectional questionnaire study. A self-administered questionnaire will be used to assess their satisfaction with current clinical services, preferences for location, frequency and provider of HIV services, as well as expectations and concerns. Furthermore, staff working at the different HIV-care to community-based organizations (CBOs) and the health care workers providing HIV services will be invited to participate as well. They will also be asked to complete a self-administered questionnaire to assess knowledge and attitude, preferences for location, frequency and provider of HIV services, as well as expectation and concerns. All data collected, from patients, as well as from staff, will be anonymous.


Recruitment information / eligibility

Status Recruiting
Enrollment 370
Est. completion date July 15, 2025
Est. primary completion date December 15, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Enrolled in the Community Led Test and Treat Study at either RSAT or SWING - According to the inclusion criteria of the Community Led Test and Treat Study, participants will be at least 18 years of age - HIV-infected and receiving ART - Willing to participate in the survey Exclusion Criteria: N/A

Study Design


Related Conditions & MeSH terms


Intervention

Other:
questionnaires survey
The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.

Locations

Country Name City State
Thailand The Thai Red Cross AIDS Research Centre Bangkok

Sponsors (1)

Lead Sponsor Collaborator
Thai Red Cross AIDS Research Centre

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Preferences for differentiated models of service delivery A self-administered questionnaire was developed to assess preferences for location, frequency and provider for different aspects of HIV care. For HIV-care to community-based organizations staff and health care workers, additional questions regarding attitudes and knowledge regarding differentiated service delivery will be included. 6 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2